C1q-Mediated Repression of Human Monocytes Is Regulated by Leukocyte-Associated Ig-Like Receptor 1 (LAIR-1)
- 44 Downloads
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by abnormal function of both the innate and the adaptive immune system, leading to a loss of tolerance to self-antigens. Monocytes are a key component of the innate immune system and are efficient producers of multiple cytokines. In SLE, inappropriate activation of monocytes is thought to contribute to the loss of self-tolerance. In this study, we demonstrate that type 1 interferon (IFN) production by CpG-challenged monocytes can be suppressed by C1q through activating leukocyte-associated Ig-like receptor-1 (LAIR-1), which contains immunoreceptor tyrosine-based inhibition motifs (ITIMs). The phosphorylation of LAIR-1 and the interaction of LAIR-1 with SH2 domain-containing protein tyrosine phosphatase-1 (SHP-1) were enhanced after LAIR-1 engagement by C1q. Moreover, engagement of LAIR-1 by C1q inhibited nuclear translocation of interferon regulatory factor (IRF)-3 and IRF5 in CpG-stimulated monocytes. These data suggest a model in which LAIR-1 engagement by C1q helps maintain monocyte tolerance, specifically with respect to Toll-like receptor-9-mediated monocyte activation.
Early studies on the pathogenesis of systemic lupus erythematosus (SLE) focused on the adaptive immune system, since B and T lymphocyte abnormalities were thought to be the primary cause of autoimmunity. However, it is now increasingly recognized that components of the innate immune system also play an essential role in SLE (1, 2, 3, 4, 5).
Monocytes are myeloid cells that play a key role in innate immunity and are efficient producers of proinflammatory cytokines and type 1 interferons (IFNs), IFNα and IFNβ, when stimulated by pathogen-associated molecular patterns (PAMPs) such as unmethylated bacterial DNA or damage-associated molecular patterns (DAMPs) such as apoptotic debris (2,5,6). Numerous monocyte defects involving aberrant activation and dysregulation of cytokine production have been identified in SLE patients (1,3). Notably, increased levels of type 1 IFN are seen in virtually all pediatric patients and a substantial percentage of adult patients. High IFN levels are a feature of some unaffected first-degree relatives as well (7,8).
TLR9, expressed by B cells, macrophages, monocytes, dendritic cells (DCs) and plasmacytoid DCs (pDCs), recognizes CpG, which mimics bacterial DNA (9, 10, 11, 12, 13). CpG 2216 is a prototype of the class of CpG (CPG-A), which preferentially activates myeloid cells as opposed to B cells (14). Human monocytes exposed to CpG-A can differentiate into DCs and produce a number of cytokines including interleukin (IL)-6, IL-12, tumor necrosis factor (TNF)-α and type I IFN (15). When TLR9 associates with CpG motifs in the endosome, it recruits MyD88; the TLR9/MyD88 complex leads to activation of interferon regulatory factors (IRFs) (16,17). IRFs including IRF3, IRF5 and IRF7 are phosphorylated and translocate into the nucleus, where they regulate transcription of type 1 IFN mRNA. IRF3 and IRF8 cooperatively regulate IFNβ production in monocytes stimulated with TLR ligands such as LPS (TLR4), Pam3csk4 (TLR2) or viral infection (18), whereas IRF3 cooperates with IRF7 to regulate IFNβ production in pDCs on TLR9 stimulation (19). Secreted type 1 IFNs bind to the IFN receptor (IFNR) acting in an autocrine manner to induce the expression of a set of secondary IFN response genes (IFN signature genes [ISGs]) such as Mx1 and OAS1 (20). Expression of these genes is tightly regulated by type 1 IFNs through the consensus IFN-stimulated response elements (20,21). IRF5 also regulates transcription of the proinflammatory cytokines IL-6 and TNFα (22); IRF5 and nuclear factor (NF)-κB p50 coregulate IL-6 in TLR9-stimulated human plasmacytoid DCs (pDCs) (23). Genetic polymorphisms of IRF3, IRF5 and IRF7 have been associated with susceptibility to SLE (17,24) and elevated levels of nuclear IRF5 have been demonstrated in monocytes of SLE patients (4).
A Src family kinase (SFK)-driven tyrosine phosphorylation pathway at the plasma membrane is upstream of and required for TLR9/MyD88 activation in endosomes (12). This result suggests that a potential CpG-sensing receptor is localized at the plasma membrane and may activate SFKs. Two SFKs, Hck and Lyn, are phosphorylated in monocytes after stimulation by CpG and induce actin cytoskeleton reorganization. They also activate the TLR9/MyD88 signaling cascade (12). The activation of SFKs is implemented through the catalytic activity of the kinase domain and through proteinprotein interactions of the regulatory SH2 and SH3 domains (25,26). Regulation of SFKs is modulated by C-Src kinase (Csk), which phosphorylates the C-terminal tyrosine of SFK, resulting in a catalytically inactive conformation (27). Although much is understood regarding the production of IFN downstream of TLR9, the membrane proximal molecular events that suppress these pathways to prevent overproduction of cytokines have not been well described.
Leukocyte-associated Ig-like receptor-1 (LAIR-1) is an inhibitory immune receptor with immunoreceptor tyrosine-based inhibition motifs (ITIMs). It is expressed on human myeloid and lymphoid cells, including NK cells, T cells, B cells and monocytes; monocyte-derived DCs; and CD34+ hematopoietic progenitor cells (28, 29, 30, 31, 32). LAIR-1 engagement inhibits the differentiation of peripheral blood precursors into DCs (33,34). On antibody-mediated cross-linking, the tyrosines in the ITIMs of LAIR-1 become phosphorylated; phosphorylation of both ITIMs is required for full inhibition of cellular activation (30,35). Phosphorylation of LAIR-1 is inhibited by PP2, a SFK inhibitor, suggesting that the kinase responsible for LAIR-1 phosphorylation is an SFK such as Lck, Hck or Lyn (36). Both human and mouse LAIR-1 are associated with Csk (30,35). Engagement of LAIR-1 recruits SH2 domain-containing protein tyrosine phosphatase-1 (SHP-1), which negatively regulates intracellular signaling (36). In NK cells, SHP-1 is associated with LAIR-1 upon stimulation by monoclonal anti-LAIR-1 antibody (31). Engagement of LAIR-1 by collagen recruits SHP-1, which negatively regulates intracellular signaling (36). SHP-1 appears to be important for negative regulation of type 1 IFN production and consequent protection against SLE-like inflammation (24,37).
The complement component C1q and extracellular matrix collagens are functional ligands for LAIR-1 and directly inhibit immune cell activation (34,38,39). C1q has been shown to regulate cytokine production and MyD88-dependent TLR-mediated signaling in murine bone marrow-derived DCs (40) and to inhibit IFNα production by human pDCs in response to stimulation by TLR ligands in vitro (34). Moreover, C1q deficiency has been associated with abnormal production of IFNα by pDCs in SLE patients (41).
Here, we set out to define how C1q suppresses CpG-mediated activation of monocytes. First, we demonstrate that CpG-induced production of type 1 IFN by monocytes is suppressed by C1q or anti-LAIR-1 monoclonal antibodies (mAbs) and is characterized by less nuclear translocation of IRFs. C1q-mediated suppression did not occur in cells transfected with LAIR-1 siRNA, confirming the importance of LAIR-1 to this inhibitory pathway. CpG alone augmented an interaction between LAIR-1 and the inactive form of Hck. However, when LAIR-1 was engaged by C1q or anti-LAIR-1 antibody in CpG-stimulated monocytes, the interaction between Hck and LAIR-1 was abrogated, and an interaction between SHP-1 and LAIR-1 was evident. Interestingly, we also found that LAIR-1 mediates a ligand-independent suppression of cytokine production. These findings demonstrate that C1q and LAIR-1 are dynamically involved in monocyte homeostasis.
Materials and Methods
Fluorochrome-conjugated and unconjugated antibodies were purchased: phycoerythrin (PE)-labeled or unlabeled mouse anti-human LAIR-1 (DX26; BD Pharmingen [BD Biosciences, San Jose, CA, USA]) for flow cytometry or stimulation; goat anti-human LAIR-1 (T-15, Santa Cruz Biotechnology, Dallas, TX, USA) for Western blotting; mouse anti-SHP-1 (D-11, Santa Cruz Biotechnology); rabbit anti-Hck (Abcam, Cambridge, MA, USA); mouse anti-phosphoSrc (Invitrogen [Thermo Fisher Scientific Inc., Waltham, MA, USA]); rabbit anti-IRF3 (Cell Signaling Technology, Danvers, MA, USA); rabbit anti-IRF5 (Protein Tech, Chicago, IL, USA); mouse anti-phospho-IkBα (Ser32/36; Cell Signaling Technology); mouse anti-phospho-IkBα (Cell Signaling Technology); mouse anti-lamin A/C (Sigma-Aldrich, St. Louis, MO, USA); mouse anti-β actin (AC-15, Sigma-Aldrich); rabbit anti-GAPDH (anti-glyceraldehyde-3-phosphate dehydrogenase) (Cell Signaling Technology); anti-CD11b, anti-CD14 and isotype-matched control antibodies (BD Pharmingen [BD Biosciences]); and human Fc receptor blocking solution (Biolegend, San Diego, CA, USA). Cell culture reagents included the following: Ficoll-plaque plus (GE Healthcare, London, UK); penicillin/streptomycin, RPMI 1640, L-glutamine and HEPES (all from Gibco/Invitrogen [Thermo Fisher Scientific]); heat-inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT, USA); and X-VIVO serum-free media (Lonza, Basel, Switzerland). Other reagents used included: C1q from Complement Technology (Tyler, TX, USA); CpG 2216 (Invitrogen [Thermo Fisher Scientific]); 1× RIPA cell lysis buffer (Invitrogen [Thermo Fisher Scientific]); protease inhibitor cocktail (Pierce, Waltham, MA, USA); phosphatase inhibitors (Pierce); formaldehyde, Triton X-100 and NP-40 (Sigma-Aldrich); Tween-20 (Fisher Scientific [Thermo Fisher Scientific]); and phosphate-buffered saline (PBS) and distilled water (Gibco/Invitrogen [Thermo Fisher Scientific]). Proteins and culture reagents were endotoxin-tested (<0.1 Endotoxin Units [EU]/mL) either by the manufacturer or by using a limulus amebocyte lysate assay kit performed per the manufacturer’s instructions (Charles River Endosafe, Kingston, NY, USA).
Human Monocyte Isolation, Culture and Stimulation
Human peripheral blood mononuclear cells (PBMCs), obtained according to institutional guidelines of the Feinstein Institute for Medical Research, were isolated from the blood of healthy donors by density centrifugation (New York Blood Center, New York, NY, USA). Monocytes were negatively enriched by using a human monocyte enrichment kit (Stemcell Technologies, Vancouver, BC, Canada). Purity of monocytes (∼90% CD11b+ CD14+) was assayed by flow cytometry. Purified monocytes (1 × 106 cells/mL) were immediately stimulated for indicated times until 30 min with CpG 2216 (5 µmol/L), C1q (25 µg/mL) or anti-LAIR-1 antibody (10 µg/mL) in X-VIVO serum-free medium and harvested at the indicated time points. For cytokine assay, cells were cultured in U-bottom 96-well plates (Nunc, Waltham, MA, USA) containing complete media (RPMI-1640 containing 2 mmol/L L-glutamine, 10 mmol/L HEPES, 50 IU/mL penicillin, 50 mg/mL streptomycin and 10% FBS).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted with an RNeasy kit (Qiagen, Hilden, Germany) and subjected to reverse transcription with an iScript cDNA synthesis kit (BioRad, Hercules, CA, USA). cDNA was analyzed by quantitative polymerase chain reaction (qPCR) by using a LightCycler 480 master mix with TaqMan probes (Applied Biosystems [Thermo Fisher Scientific]) against human IFNα4 (Hs01681284), IFNβ1 (Hs01077958), MX1 (Hs00182073), OAS1 (Hs00242942), IL-6 (Hs00985639), TNFα (Hs00174128) and Polr2A (Hs00172187). Data were normalized to Polr2a; relative induction was calculated by ΔΔCt.
Cytokine analysis for IL-6 and TNFα was performed using a Human ProInflammatory 7-Plex Ultra-Sensitive Kit (Meso Scale Discovery [MSD], Rockville, MD). MSD plates were analyzed on the MS2400 imager (MSD). Assay was performed according to the manufacturer’s instructions. All standards and samples were measured in duplicate.
Isolation of Nuclear Fractions
The NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific [Thermo Fisher Scientific]) was used for nuclear extraction following the manufacturer’s protocol. The efficiency of nuclear fractions was determined by immunoblotting for lamin.
Unstimulated or stimulated monocytes were washed three times with ice-cold PBS, fixed with 4% (v/v) paraformaldehyde and permeablized with 0.2% Triton X-100. Cells were seeded (2 × 105 cells/mL) on slides by using cytospin and blocked with 2% goat serum and 2% bovine serum albumin (Invitrogen [Thermo Fisher Scientific]). Cells were incubated overnight at 4°C with anti-IRF3 antibody (1:100) and washed and incubated with Alexa Fluor 488-labeled goat anti-mouse antibody (1:200; Invitrogen [Thermo Fisher Scientific]). Nuclei were stained with propidium iodide (0.5 µg/mL; Sigma-Aldrich). Cells were washed and mounted, and confocal images were captured by FluoView 300 (Olympus, Center Valley, PA, USA) and analyzed by using Axio vision 4.8 software (Zeiss, Jena, Germany).
Transfection and Flow Cytometry
In RNA interference assays, monocytes were transfected by using an AmaxaNucleofector kit (Lonza). Transfection efficiency was over 40%. siRNAs for LAIR-1 or control siRNA were from Qiagen. The target sequence of human LAIR-1 is CAGCATCCAGAAGGTTCGTTA. The efficiency of knockdown was determined by flow cytometry (FACS verse; BD Biosciences) with PE-labeled anti-human LAIR-1 antibody. Data were analyzed by using FlowJo software (Tree Star; see https://doi.org/www.flowjo.com/).
Immunoprecipitation and Western Blot Analysis
Unstimulated or CpG-stimulated monocytes (2–5 × 106 cells/mL) were washed in ice-cold PBS and lysed in 1× RIPA buffer containing complete protease inhibitor mixture (Roche, Basel, Switzerland) and phosphatase inhibitor (Pierce). For immunoprecipitation, cell lysates were then diluted 10-fold with lysis buffer and anti-LAIR-1 antibody before being incubated with precleared protein G-dynabeads (Life Technologies [Thermo Fisher Scientific]). Immunoblotting of bound proteins was performed with the indicated antibodies.
To determine tyrosine phosphorylated LAIR-1, cell lysates from monocytes (7 × 106) stimulated without CpG or with CpG only, CpG plus C1q or CpG plus anti-LAIR-1 antibody were incubated with human phosphoimmunoreceptor array membranes (Proteome Profiler Array; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. Phosphorylation levels of individual analytes were determined by average pixel density of duplicate spots; values were obtained after subtraction of background and were normalized to positive control spots.
Statistical analyses were performed with Prism 5.0 (GraphPad, La Jolla, CA, USA). P values were calculated by using a two-tailed unpaired Student t test or two-way ANOVA. P values of <0.05 were considered significant: *p < 0.05, **p < 0.01 and ≤ 0.001 (Student t test).
C1q and LAIR-1 Modulate the Expression of Multiple Genes in Human Monocytes Stimulated with CpG
C1q and LAIR-1 Inhibit the Nuclear Translocation of IRFs Mediated by CpG Stimulation
LAIR-1 Sequesters the Inactive Hck during CpG-Mediated Activation While C1q Leads to SHP-1 Engagement with LAIR-1
To explore the dynamic interactions of these proteins, we performed the same coimmunoprecipitation study at different time points after CpG stimulation in the absence or presence of C1q (5),15 and 30 min). The results of this analysis suggested that Csk constitutively binds to LAIR-1. Hck binds to LAIR-1 and is inactivated, presumably by Csk, after CpG stimulation. However, on engagement by C1q, LAIR-1 changes binding partners and associates with SHP-1 (Figure 4B).
In this study, we demonstrate a suppressive mechanism of C1q in human monocytes. Monocytes have been increasingly recognized to play a role in both the initiation and propagation of SLE given their functions in phagocytosis and cytokine production (1,5,6,42). In particular, in the pristane-induced model of murine lupus, monocytes play a key pathogenic role by acting as a major producer of type I IFNs (5). Human monocytes express TLR9 and respond to CpG (13,43). We observed that C1q or anti-LAIR-1 antibody inhibited CpG-mediated nuclear translocation of IRF3 and IRF5 and phosphorylation of IkBα. The fact that the suppression of CpG-mediated activation of monocytes by C1q was reversed by LAIR-1-specific siRNA demonstrated that the suppressive effects of C1q are LAIR-1 dependent. Transfection of monocytes with LAIR-1 siRNA led to higher baseline levels of cytokine transcription, demonstrating a role for LAIR-1 in monocyte homeostasis. Moreover, CpG did not increase cytokine expression in monocytes lacking LAIR-1 expression, suggesting that CpG stimulation blocks the constitutive inhibitory function of LAIR-1. Our findings demonstrate a contribution of C1q deficiency to SLE that is independent of the role of C1q in clearance of apoptotic debris.
IFNs are key mediators of host defense to viral and bacterial infection. They are also thought to be involved in the pathogenesis of SLE (17,20,44,45). Patients treated with IFN for hepatitis C infection develop anti-nuclear antibodies or overt SLE (46). Serum levels of IFN correlate with disease activity in SLE. We demonstrate that C1q and LAIR-1 signaling suppresses the activation of IRFs, and this mechanism regulates the transcription of multiple cytokines upon CpG stimulation in human monocytes.
An absence of C1q has been shown to lead to enhanced IFN production by both human and mouse pDCs (39,41). We also have tested whether C1q inhibits myeloid cell activation by other PAMPs such as LPS or high-mobility group protein B1 (HMGB1). Interestingly, C1q also has a suppressive function in the HMGB1-mediated production of IFN (unpublished data). Kanakoudi-Tskalidou et al. (7) showed that mean serum levels of HMGB1 are positively correlated with levels of IFNα and the expression of LAIR-1 on pDCs of SLE patients is significantly lower than its expression on pDCs of healthy controls (47). These findings suggest that C1q/LAIR-1 signaling mediates a major inhibitory pathway for the innate immune response. Manipulating LAIR-1 may be a strategy for regulating inflammation and, specifically, disease activity in SLE. Notably, we also have observed that the C1q collagen tail, which engages LAIR-1, inhibits TLR signaling. A recent report showed that collagenous domains of C-type lectin surfactant protein-D (SP-D) bind to LAIR-1 and regulate FcαR-mediated reactive oxygen production in neutrophils (48). These results suggest that LAIR-1 engagement by collagen-like domains may be a therapeutic strategy for controlling inflammation in SLE and inflammatory conditions.
The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.
This work was supported by National Institutes of Health Grant R01AR-049126 to B Diamond and an Arthritis Foundation Fellowship to M Son. We would like to thank Sylvia Jones for expert secretarial assistance and the flow cytometry and imaging cores of the Feinstein Institute for Medical Research and Barbara Sherry, Frances Santiago-Schwarz, Sun-Jung Kim and Yong-Rui Zou for review of the manuscript. We also thank Frances SantiagoSchwarz for initiating our studies of LAIR-1.
- 29.van der Vuurst de Vries AR, Clevers H, Logtenberg T, Meyaard L. (1999) Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling. Eur. J. Immunol. 29:3160–7.CrossRefPubMedGoogle Scholar
- 42.Byrne JC, et al. (2012) Genetics of SLE: functional relevance for monocytes/macrophages in disease. Clin. Dev. Immunol. 2012:582352.Google Scholar
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)